What is BHVN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.82B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BHVN?

P/E (TTM) is n/a and 52-week range is $7.48 to $18.57 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BHVN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BHVN?

The company profile lists net income (TTM) near $-699M, EPS (TTM) near $-4.64 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Biohaven Ltd based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Haven, Connecticut, US, 150.6M shares outstanding, ISIN VGG1110E1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Biohaven Ltd

$BHVN

Health Care · Biotechnology

IR Run Scenarios

$12.08

+1.26%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company is headquartered in New Haven, Connecticut and currently employs 274 full-time employees. The company went IPO on 2022-09-23. The company is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

Employees

274

Website

www.biohaven.com/

IPO

2022-09-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)